BiotechTube

Amevive (Alefacept) + Placebo

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lichen Planus

Conditions

Lichen Planus

Trial Timeline

Apr 1, 2004 → Dec 1, 2004

NCT ID
NCT00135733

About Amevive (Alefacept) + Placebo

Amevive (Alefacept) + Placebo is a phase 2 stage product being developed by Biogen for Lichen Planus. The current trial status is terminated. This product is registered under clinical trial identifier NCT00135733. Target conditions include Lichen Planus.

What happened to similar drugs?

0 of 2 similar drugs in Lichen Planus were approved

Approved (0) Terminated (0) Active (2)
🔄Dupilumab + PlaceboSanofiPhase 3
🔄Dupilumab + PlaceboSanofiPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00135733Phase 2Terminated

Competing Products

12 competing products in Lichen Planus

See all competitors
ProductCompanyStageHype Score
LP-10 (Liposomal Tacrolimus)Lipella PharmaceuticalsPhase 2
29
Tacrolimus cream + Clobetasol creamAstellas PharmaPhase 2
35
Baricitinib 4 milligram Oral TabletEli LillyPhase 2
39
pimecrolimus and clobetasol + clobetasol 0.05% creamNovartisPhase 2
35
Pimecrolimus 1% creamNovartisPhase 2
35
secukinumab 300 mg Q4W + secukinumab 300 mg Q2WNovartisPhase 2
35
Apremilast + PlaceboAmgenPhase 2
31
DeucravacitinibBristol Myers SquibbPhase 2
35
Dupilumab + PlaceboSanofiPhase 3
44
Dupilumab + PlaceboSanofiPhase 3
44
Ruxolitinib cream + Vehicle creamIncytePhase 2
32
Ruxolitinib cream + Vehicle creamIncytePhase 2
32